Back
 JCT  Vol.3 No.6 A , November 2012
Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody
Abstract: Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.
Cite this paper: K. Lam and V. Lee, "Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody," Journal of Cancer Therapy, Vol. 3 No. 6, 2012, pp. 902-911. doi: 10.4236/jct.2012.326116.
References

[1]   http://globocan.iarc.fr/factsheets/cancers/colorectal.asp

[2]   Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB Signalling Network,” Nature Reviews Molecular Cell Biology, Vol. 2, No. 2, pp. 127-137. doi:10.1038/35052073

[3]   L. N. Klapper, H. Waterman, M. Sela and Y. Yarden, “Tumor-inhibitory Antibodies to HER-2/ErbB-2 May Act by Recruiting c-Cbl and Enhancing Ubiquitination of HER-2,” Cancer Research, Vol. 60, No. 13, 2000, pp. 3384-3388.

[4]   M. A. Olayioye, R. M. Neve, H. A. Lane and N. E. Hynes, “The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer,” The EMBO Journal, Vol. 19, No. 13, 2000, pp. 3159-3167. doi:10.1093/emboj/19.13.3159

[5]   A. Citri and Y. Yarden, “EGF-ERBB Signalling: Towards the Systems Level,” Nature Reviews Molecular Cell Biology, Vol. 7, No. 7, 2006, pp. 505-516. doi:10.1038/nrm1962

[6]   N. E. Hynes and H. A. Lane, “ERBB receptors and Cancer: The Complexity of Targeted Inhibitors,” Nature Reviews Cancer, Vol. 5, No. 5, 2005, pp. 341-354. doi:10.1038/nrc1609

[7]   J. Mendelsohn and J. Baselga, “Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer,” Journal of Clinical Oncology, Vol. 21, No. 14, 2003, 2787-2799. doi:10.1200/JCO.2003.01.504

[8]   J. Sato, T. Kawamoto, A. Le, J. Mendelsohn, J. Polikoff and G. Sato, “Biological Effects in Vitro of Monoclonal Antibodies to Human Epidermal Growth Factor Receptors,” Molecular Biology and Medicine, Vol. 1, No. 5, 1983, pp. 511-529.

[9]   H. Masui, T. Kawamoto, J. D. Sato, B. Wolf, G. Sato and J. Mendelsohn, “Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies,” Cancer Research, Vol. 44, No. 3, 1984, pp. 1002-1007.

[10]   S. Li, K. R. Schmitz, P. D. Jeffrey, J. J. W. Wiltzius, P. Kussie and K. M. Ferguson, “Structural Basis for Inhibition of the Epidermal Growth Factor Receptor by Cetuximab,” Cancer Cell, Vol. 7, No. 4, 2005, pp. 301-311. doi:10.1016/j.ccr.2005.03.003

[11]   H. Kimura, K. Sakai, T. Arao, T. Shimoyama, T. Tamura and K. Nishio, “Antibody-Dependent Cellular Cytotoxicity of Cetuximab Against Tumor Cells with Wild-Type or Mutant Epidermal Growth Factor Receptor,” Cancer Science, Vol. 98, No. 8, 2007, pp. 1275-1280. doi:10.1111/j.1349-7006.2007.00510.x

[12]   Y. Kawaguchi, K. Kono, K. Mimura, H. Sugai, H. Akaike and H. Fujii, “Cetuximab Induce Antibody-Dependent Cellular Cytotoxicity against EGFR-Expressing Esophageal Squamous Cell Carcinoma,” International Journal of Cancer, Vol. 120, No. 4, 2007, pp. 781-787. doi:10.1002/ijc.22370

[13]   E. Van Cutsem, C-H. Kohne, E. Hitre, J. Zaluski, C-R. Chang Chien, A. Makhson, et al., “Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 360, No. 14, 2009, pp. 1408-1417. doi:10.1056/NEJMoa0805019

[14]   E. Van Cutsem, C-H. K?hne, I. Láng, G. Folprecht, M. P. Nowacki, S. Cascinu, et al., “Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status,” Journal of Clinical Oncology, Vol. 29, No. 15, 2011, pp. 2011-2019. doi:10.1200/JCO.2010.33.5091

[15]   C. Bokemeyer, E. Van Cutsem, P. Rougier, F. Ciardiello, S. Heeger, M. Schlichting, et al., “Addition of Cetuximab to Chemotherapy as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer: Pooled Analysis of the Crystal and OPUS Randomised Clinical Trials,” European Journal of Cancer, Vol. 48, No. 10, 2012, pp. 1466-1475. doi:10.1016/j.ejca.2012.02.057

[16]   J.-Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, et al., “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study,” Journal of Clinical Oncology, Vol. 28, No. 31, 2010, pp. 4697-4705. doi:10.1200/JCO.2009.27.4860

[17]   C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. de Braud, G. Schuch, A. Zubel, et al., “Efficacy According to Biomarker Status of Cetuximab Plus FOLFOX-4 as first-Line Treatment for Metastatic Colorectal Cancer: the OPUS Study,” Annals of Oncology, Vol. 22, No. 7, 2011, 1535-1546. doi:10.1093/annonc/mdq632

[18]   R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, et al., “Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 10, 2008, pp. 1626-1634. doi:10.1200/JCO.2007.14.7116

[19]   T. S. Maughan, R. A. Adams, C. G. Smith, A. M. Meade, M. T. Seymour, R. H. Wilson, et al., “Addition of Cetuximab to Oxaliplatin-Based First-Line Combination Chemotherapy for Treatment of Advanced Colorectal Cancer: Results of the Randomised Phase 3 MRC COIN Trial,” The Lancet, Vol. 377, No. 9783, 2011, pp. 2103- 2114. doi:10.1016/S0140-6736(11)60613-2

[20]   K. M. Tveit, T. Guren, B. Glimelius, P. Pfeiffer, H. Sorbye, S. Pyrhonen, et al., “Phase III Trial of Cetuximab with Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: the NORDIC-VII Study,” Journal of Clinical Oncology, Vol. 30, No. 15, 2012, pp. 1755-1762. doi:10.1200/JCO.2011.38.0915

[21]   H. S?rbye, B. Glimelius, ?. Berglund, T. Fokstuen, K. M. Tveit, M. Br?ndengen, et al., “Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined with Oxaliplatin as First-Line Treatment of Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 31-38. doi:10.1200/jco.2004.05.188

[22]   A. F. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. A. Abubakr, M. P. Lutz, et al., “EPIC: Phase III Trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 14, 2008, pp. 2311-2319. doi:10.1200/JCO.2007.13.1193

[23]   C. Langer, J. Kopit and M. Awad, “Analysis of KRAS Mutations in Patients with Metastatic Colorectal Cancer Receiving Cetuximab in Combination with Irinotecan: Results from the EPIC Trial,” Annals of Oncology, Vol. 26, Suppl. 8, 2008, p. viii133.

[24]   M. Peeters, T. J. Price, A. Cervantes, A. F. Sobrero, M. Ducreux, Y. Hotko, et al., “Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 28, No. 31, 2010, pp. 4706-4713. doi:10.1200/JCO.2009.27.6055

[25]   D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, et al., “Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 351, No. 4, 2004, pp. 337-345. doi:10.1056/NEJMoa033025

[26]   D. J. Jonker, C. J. O’Callaghan, C. S. Karapetis, J. R. Zalcberg, D. Tu, H.-J. Au, et al., “Cetuximab for the Treatment of Colorectal Cancer,” New England Journal of Medicine, Vol. 357, No. 20, 2007, pp. 2040-2048. doi:10.1056/NEJMoa071834

[27]   C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O’Callaghan, D. Tu, N. C. Tebbutt, et al., “K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer,” New England Journal of Medicine, Vol. 359, No. 17, 2008, pp. 1757-1765. doi:10.1056/NEJMoa0804385

[28]   H.-J. Au, C. S. Karapetis, C. J. O'Callaghan, D. Tu, M. J. Moore, J. R. Zalcberg, et al., “Health-Related Quality of Life in Patients with Advanced Colorectal Cancer Treated with Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial,” Journal of Clinical Oncology, Vol. 27, No. 11, 2009, pp. 1822-1828. doi:10.1200/JCO.2008.19.6048

[29]   E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, et al., “Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 25, No. 13, 2007, pp. 1658-1664. doi:10.1200/JCO.2006.08.1620

[30]   F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, et al., “Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells,” Clinical Cancer Research, Vol. 6, No. 9, 2000, pp. 3739-3747.

[31]   R. M. Shaheen, S. A. Ahmad, W. Liu, N. Reinmuth, Y. D. Jung, W. W. Tseng, et al., “Inhibited Growth of Colon Cancer Carcinomatosis by Antibodies to Vascular Endothelial and Epidermal Growth Factor Receptors,” British journal of cancer, Vol. 85, No. 4, 2001, pp. 584-589. doi:10.1054/bjoc.2001.1936

[32]   Y. D. Jung, P. F. Mansfield, M. Akagi, A. Takeda, W. Liu, C. D. Bucana, et al., “Effects of Combination Anti-Vascular Endothelial Growth Factor Receptor and Anti-Epidermal Growth Factor Receptor Therapies on the Growth of Gastric Cancer in a Nude Mouse Model,” European Journal of Cancer, Vol. 38, No. 8, 2002, pp. 1133-1140. doi:10.1016/S0959-8049(02)00013-8

[33]   J. R. Tonra, D. S. Deevi, E. Corcoran, H. Li, S. Wang, F. E. Carrick, et al., “Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy,” Clinical Cancer Research, Vol. 12, No. 7, 2006, pp. 2197-2207. doi:10.1158/1078-0432.CCR-05-1682

[34]   L. B. Saltz, H.-J. Lenz, H. L. Kindler, H. S. Hochster, S. Wadler, P. M. Hoff, et al., “Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared with Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study,” Journal of Clinical Oncology, Vol. 25, No. 29, 2007, pp. 4557-4561. doi:10.1200/JCO.2007.12.0949

[35]   J. Tol, M. Koopman, A. Cats, C. J. Rodenburg, G. J. M. Creemers, J. G. Schrama, et al., “Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 360, No. 6, 2009, pp. 563-572. doi:10.1056/NEJMoa0808268

[36]   J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, et al., “A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared with Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 27, No. 5, 2009, pp. 672-680. doi:10.1200/JCO.2008.19.8135

[37]   B. Chibaudel, F. Maindrault-Goebel, G. Lledo, L. Mineur, T. André, M. Bennamoun, et al., “Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study,” Journal of Clinical Oncology, Vol. 27, No. 34, 2009, pp. 5727-5733. doi:10.1200/JCO.2009.23.4344

[38]   R. A. Adams, A. M. Meade, M. T. Seymour, R. H. Wilson, A. Madi, D. Fisher, et al., “Intermittent versus Continuous Oxaliplatin and Fluoropyrimidine Combination Chemotherapy for First-Line Treatment of Advanced Colorectal Cancer: Results of the Randomised Phase 3 MRC COIN Trial,” the Lancet Oncology, Vol. 12, No. 7, 2011, pp. 642-653. doi:10.1016/S1470-2045(11)70102-4

[39]   A. Grothey, M. M. Sugrue, D. M. Purdie, W. Dong, D. Sargent, E. Hedrick, et al., “Bevacizumab Beyond First Progression Is Associated with Prolonged Overall Survival in Metastatic Colorectal Cancer: Results from a Large Observational Cohort Study (BRiTE),” Journal of Clinical Oncology, Vol. 26, No. 33 2008, pp. 5326-5334. doi:10.1200/JCO.2008.16.3212

[40]   D. Santini, F. Loupakis, B. Vincenzi, I. Floriani, I. Stasi, E. Canestrari, et al., “High Concordance of KRAS Status between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice,” The Oncologist, Vol. 13, No. 12, 2008, pp. 1270-1275. doi:10.1634/theoncologist.2008-0181

[41]   S. Gattenlohner, B. Etschmann, V. Kunzmann, A. Thalheimer, M. Hack, G. Kleber, et al., “Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy,” Journal of Oncology, Vol. 2009, 2009, Article ID: 831626. doi:10.1155/2009/831626

[42]   D. Santini, B. Vincenzi, R. Addeo, C. Garufi, G. Masi, M. Scartozzi, et al., “Cetuximab Rechallenge in Metastatic Colorectal Cancer Patients: How to Come Away from Acquired Resistance?” Annals of Oncology, Vol. 23, No. 9, 2012, pp. 2313-2318. doi:10.1093/annonc/mdr623

[43]   J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramee, et al., “PANERB study: Panitumumab after Cetuximab-Based Regimen Failure,” Journal of Clinical Oncology, Vol. 28, No. 15, 2010, p. e140000.

[44]   R. C. Wadlow, A. F. Hezel, T. A. Abrams, L. S. Blaszkowsky, C. S. Fuchs, M. H. Kulke, et al., “Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab,” The Oncologist, Vol. 17, No. 1, 2012, pp. 14, pp. e27-e34. doi:10.1634/theoncologist.2011-0452

[45]   C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, et al., “FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology, Vol. 22, No. 2, 2004, pp. 229-237. doi:10.1200/JCO.2004.05.113

[46]   A. Grothey, D. Sargent, R. M. Goldberg, H.-J. Schmoll, “Survival of Patients with Advanced Colorectal Cancer Improves with the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment,” Journal of Clinical Oncology, Vol. 22, No. 7, 2004, pp. 1209-1214. doi:10.1200/JCO.2004.11.037

[47]   B. J, Giantonio, P. J. Catalano, N. J. Meropol, P. J. O’Dwyer, E. P. Mitchell, S. R. Alberts, et al., “Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200,” Journal of Clinical Oncology, Vol. 25, No. 12, 2007, pp. 1539-1544. doi:10.1200/JCO.2006.09.6305

[48]   R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, et al., “Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells,” Clinical Cancer Research, Vol. 14, No. 16, 2008, pp. 5069-5080. doi:10.1158/1078-0432.CCR-07-4905

[49]   G. N. Naumov, M. B. Nilsson, T. Cascone, A. Briggs, O, Straume, L. A. Akslen, et al., “Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance,” Clinical Cancer Research, Vol. 15, No. 10, 2009, pp. 3484-3494. doi:10.1158/1078-0432.CCR-08-2904

[50]   A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, J. M. Schlaeppi, et al., “Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-Blocking Antibodies in Vivo,” Cancer Research, Vol. 61, No. 13, 2001, pp. 5090-5101.

[51]   E. Norguet, L. Dahan, J. Gaudart, M. Gasmi, L. H. Ouafik, J.-F. Seitz, “Cetuximab after Bevacizumab in Metastatic Colorectal Cancer: Is It the Best Sequence?” Digestive and Liver Disease, Vol. 43, No. 11, 2011, pp. 917-919. doi:10.1016/j.dld.2011.06.002

[52]   S. Stintzing, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jager, T. Heintges, et al., “FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer—Subgroup Analysis of Patients with KRAS: Mutated Tumours in the Randomised German AIO Study KRK-0306,” Annals of Oncology, Vol. 23, No. 7, 2012, pp. 1693-1699. doi:10.1093/annonc/mdr571

 
 
Top